Friday, 29/08/2008
Product Pipeline
Clinical Pipeline Chart
To see the MedImmune Cambridge-derived clinical pipeline, please click on the icon below:
To see other development in the MedImmune pipeline, please click on the link to the main MedImmune website below:
MedImmune Proprietary Products Developed at Cambridge
We are developing five human monoclonal antibody drug candidates. CAT-354 is being developed as a treatment for severe asthma and has completed a Phase I clinical trial. GC-1008, which is being developed in collaboration with Genzyme and is in Phase I development for the treatment of idiopathic pulmonary fibrosis and oncology indications.
CAT-8015 is being developed for the treatment of B-cell malignancies. CAT-8015 is in Phase I development as a potential treatment for B-cell malignancies. CAT-2200 is in Pre-Clinical development as a potential treatment for rheumatoid arthritis. CAM-3001, in collaboration with Zenyth (acquired by CSL) is in Phase I development as a potential treatment for rheumatoid arthritis.
We have active research programmes against a number of other distinct molecular targets.
Licensed Products
MedImmune's product licensees are developing seven human monoclonal antibody drug candidates, which are at various stages of clinical development.
HUMIRA® is marketed by Abbott as a treatment for rheumatoid arthritis in over 50 countries worldwide, and for early rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease in several European countries and the US. It is also being developed for juvenile rheumatoid arthritis and chronic plaque psoriasis.
ABT-874 is being developed for Crohn’s disease and psoriasis, LymphoStat-B™ for systemic lupus erythematosus and rheumatoid arthritis, HGS-ETR1 and HGS-ETR2 for cancer, ABthrax™ for anthrax infection and MYO-029 for muscular dystrophy. Further licensed product candidates are in pre-clinical development and in discovery.
MedImmune's patent licensees are developing a further three human monoclonal antibody drug candidates, MT201 for carcinomas and IMC-11F8 and IMC-1121B for cancer.
To find out how antibodies work as therapeutics, please click on the link below: